These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
308 related items for PubMed ID: 11158042
1. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. J Clin Endocrinol Metab; 2001 Feb; 86(2):755-60. PubMed ID: 11158042 [Abstract] [Full Text] [Related]
2. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. Alexandersen P, Riis BJ, Christiansen C. J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657 [Abstract] [Full Text] [Related]
3. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F. J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794 [Abstract] [Full Text] [Related]
4. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Warming L, Ravn P, Nielsen T, Christiansen C. Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289 [Abstract] [Full Text] [Related]
5. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women. Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN. Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449 [Abstract] [Full Text] [Related]
8. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K. Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472 [Abstract] [Full Text] [Related]
9. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Warming L, Ravn P, Christiansen C. Maturitas; 2005 Feb 14; 50(2):78-85. PubMed ID: 15653003 [Abstract] [Full Text] [Related]
10. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Maturitas; 2008 Jan 20; 59(1):2-6. PubMed ID: 18063490 [Abstract] [Full Text] [Related]
11. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study. Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, Saarikoski S. J Clin Endocrinol Metab; 1997 Aug 20; 82(8):2476-82. PubMed ID: 9253321 [Abstract] [Full Text] [Related]
12. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Greenwald MW, Gluck OS, Lang E, Rakov V. Menopause; 2005 Aug 20; 12(6):741-8. PubMed ID: 16278618 [Abstract] [Full Text] [Related]
13. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. Komulainen M, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Jurvelin J, Saarikoski S. J Clin Endocrinol Metab; 1999 Feb 20; 84(2):546-52. PubMed ID: 10022414 [Abstract] [Full Text] [Related]
14. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women. Hart DM, Farish E, Fletcher CD, Barnes JF, Hart H, Nolan D, Spowart K. Osteoporos Int; 1998 Feb 20; 8(4):326-32. PubMed ID: 10024902 [Abstract] [Full Text] [Related]
15. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. Dane C, Dane B, Cetin A, Erginbas M. Gynecol Endocrinol; 2007 Jul 20; 23(7):398-403. PubMed ID: 17701771 [Abstract] [Full Text] [Related]
17. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. Gallagher JC, Fowler SE, Detter JR, Sherman SS. J Clin Endocrinol Metab; 2001 Aug 20; 86(8):3618-28. PubMed ID: 11502787 [Abstract] [Full Text] [Related]
18. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA. J Bone Miner Res; 2006 Feb 20; 21(2):283-91. PubMed ID: 16418784 [Abstract] [Full Text] [Related]
19. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. N Engl J Med; 1997 Dec 04; 337(23):1641-7. PubMed ID: 9385122 [Abstract] [Full Text] [Related]
20. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Osteoporos Int; 2003 Oct 04; 14(10):814-22. PubMed ID: 14610642 [Abstract] [Full Text] [Related] Page: [Next] [New Search]